My programs have integrated fundamental, translational, and clinical approaches to studies on hostpathogen interactions. Since the mid-90s, I have conducted tuberculosis research. I have led biomarker discovery projects funded by the NIH and through the Bill and Melinda Gates Foundation leading to numerous publications, including a seminal publication in PNAS in 2010 that defines the sero-proteome of Mycobacterium tuberculosis, and multiple grants, including two R01s on the use of RNA flow cytometry to study antigenspecific T cell activation in latent and active tuberculosis. One of these R01s was an academia-industry partnership grant to establish a new diagnostic platform, which was published in Nature Protocols in 2017. My work with M. tuberculosis proteins also led to seven patents for proteins and genes useful as vaccines and diagnostic reagents for M. tuberculosis that have generated $10M in licensing income, and I was awarded the Thomas Alva Edison Patent Award in 2009.